fiscal seem stay consist
thesi laid recent upgrad market-lead posit
solid core busi bolster addit fast-grow high-margin offer
quarter compani beat expect revenu gross order
expect revenu felt order japan risk quarter
offer above-consensu guidanc think bounc back america
oncolog gross order well broad strength across region except
anticip light result japan quiet investor concern around reimburs
chang somewhat new intervent oncolog busi given
emphasi think potenti newli acquir product
part var portfolio outpac expect order volum new
etho ai-pow adapt system multi-mod imag fusion impress us
earli etho may becom meaning growth driver next coupl
year like isnt fulli captur street model look forward deeper
insight var strategi outlook next month analyst day reiter
north american oncolog gross order growth like biggest
surpris quarter head print loudest concern
heard investor see especi posit sign var stabil
face market unpredict propos radiat oncolog
altern payment model ro-apm horizon manag upbeat
broad-bas driver portfolio offer urg focu
trailing-twelve-month ttm metric instead one quarter weve note
think may best spot weather ro-apm hesit
enthusiasm etho evid order new upgrad
europ australia week regulatori approv
anticip soon potenti late earli launch
earli day think etho could lift gross order growth rate sever quarter
come
outlook fall within guidanc think upper end rang
look quit achiev order strength throughout like fuel
revenu growth swallow recent acquisit growth
new offer could bolster sale back half fiscal year similarli
product softwar servic boost margin may set
ep beats-and-rais come quarter
valuat pt base month non-gaap ep
idc btig estim compani document
million except per share amount
varian world leader radiat therapi stereotact surgeri think offer superior technolog
faster treatment competitor rad onc market lumpi growth overal low mid-singl digit
demand halcyon product softwar offer value-ad servic drive higher growth rate
think trend continu increas order next year true spend drive
growth compani still grow ep faster peer believ deserv trade premium
final implement propos radiat oncolog altern
above-market growth oncolog gross order revenu
stabl reimburs radiat oncolog
stabl economi capital-expenditure environ
continu abil off-set impact tariff
acceler oncolog gross order revenu growth
favor reimburs radiat oncolog
posit resolut trade war/tariff
improv economi capital-expenditure environ
varian world lead
manufactur radiat therapi
brachytherapi plan
market slowdown oncolog gross order revenu growth
neg develop reimburs radiat oncolog
slump economi capital-expenditure environ
varian report total revenu continu oper exceed estim street
compani post gross oncolog order best street varian
report proton revenu model
quarter gross oncolog order y/i constant currenc includ y/i america y/i cc
emea y/i cc apac region
gross margin bp model strong oncolog gross margin quarter sg spend
percentag revenu bp higher estim spend bp lower forecast led
oper margin bp higher model tax rate higher expect due impact gilti
higher tax rate outweigh revenu margin beat quarter result two-cent miss non-
increas oncolog gross order growth emea quarter beat time increas
model percentag order convert order also increas revenu higher back half
reflect upbeat commentari anticip growth acquir product
forecast total revenu y/i midpoint guidanc rang
growth y/i project oncolog gross order repres y/i growth
actualsbtig estimate varianceoncolog revenu revenu revenu gross order gross order incom gross bp sg spend bp spend bp ebit bp tax bpssourc btig estim compani filingsvari
tweak gross margin oper margin higher go forward model non-gaap oper margin
midpoint guid also rais forecast non-gaap tax rate model
midpoint guidanc rang model call non-gaap ep top end
varian rate buy price target base month non-gaap ep estim varian trade
line comp group grow revenu ep faster rate risk rate price target includ
halcyon adopt chang oper margin capit spend slowdown hospit govern new
competit healthcar multipl gener trade lumpi quarterli result
exhibit comp tabl large-cap peer
gross incom ebit btig estim compani filingsnewold changecompanytickerr ptpricemarket cap bntm johnsonjnjnot pt bdxnot pt scientificbsxbuy factset data btig estimatespr ex-amortev/salescagr
varian incom oncolog total y/i good gross sg one-tim total oper incom loss invest incom pre-tax incom incom non- net incom continu net earn discont op non-control non- dilut share net ex select calendar loss net product product product oper ep ep btig estim compani report
varian revenu eoncolog gross america y/i net america order y/i gross emea y/i net emea order y/i gross apac order y/i net apac y/i gross y/i net order y/i trail month gross trail month net y/i contract y/i oncolog y/i gross y/i y/i y/i gross y/i y/i y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
